The largest database of trusted experimental protocols

Agilent 4 44k gene expression arrays

Manufactured by Agilent Technologies

The Agilent 4 × 44K gene expression arrays are high-density microarray products designed for comprehensive whole-genome expression analysis. Each array contains 44,000 probes that target well-characterized genes and transcripts, providing a thorough coverage of the human, mouse, or rat transcriptome.

Automatically generated - may contain errors

5 protocols using agilent 4 44k gene expression arrays

1

Two-color Agilent 4x44K gene expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two-color human Agilent 4×44K gene-expression arrays were used, as described by the manufacturer, comparing signal from control cells (Cy3-labelled) and test cells (Cy5-labelled). Array elements were filtered for those meeting confidence thresholds for spot size, architecture, and level above local background. These criteria are a feature of the Agilent gene expression software package for Agilent 4×44k arrays.
+ Open protocol
+ Expand
2

Gene Expression Profiling of TLR9 and MyD88 Knockdown

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were transduced with shRNAs, puro-selected and harvested at indicated times after shRNA induction. RNA was isolated using RNEasy mini kits (Qiagen). Gene expression was assessed using two-color human Agilent 4 × 44K gene expression arrays following the manufacturers protocol. Briefly, control shSC4 (control, Cy3-labelled) RNA was compared to RNA from cells with shRNAs targeting TLR9 (C4), TLR9 (D7), MyD88 (A7), MyD88 (B3) (Cy5-labelled) at each of the indicated time points. Array elements were filtered for spot quality using Agilent Feature Extraction software version 10.7, specific genes were determined to be downregulated if the log2 fold change (comparing control shSC4 to shRNA for TLR9) was less than −0.3 for at least 3 of the 4 time points (shTLR9) per cell line. Gene expression data have been deposited in Gene Expression Omnibus (GEO) under accession GSE99276. Signature enrichment was performed as previously described 32 (link). Briefly, downregulated genes were tested for overlap with published gene signatures in a 2×2 contingency table using a Fisher’s exact test.
+ Open protocol
+ Expand
3

CTC Isolation and Transcriptome Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
CTC isolation was performed from 7.5 ml of peripheral blood from advanced NSCLC patients or healthy donors using the EpCAM-based CELLectionTM Epithelial Enrich Dynabeads® kit (Invitrogen, Dynal; Oslo, Norway) according to manufacturers’ instructions. Isolated CTCs were resuspended in RNA later® (Ambion; Foster City, CA, USA) and preserved at −80°C until use.
Total RNA extraction, Complete Whole Transcriptome Amplification (WTA2, Sigma Aldrich) and gene expression array was performed as described by Barbazan et al.11 (link). Briefly, total RNA was extracted with the QIAmp viral RNA mini kit (Qiagen, Valencia, CA, USA) specifically designed for very low cellularity samples. Subsequent pure RNA was then subjected to Complete Whole Transcriptome Amplification PCR for 20 cycles using the maximum amount of RNA; Cy3 labelling and hybridization onto Agilent 4 × 44 k gene expression arrays. Upon hybridization, signal was captured and submitted to Significance Analysis for Microarray to identify differentially expressed genes (Supplementary Material and Methods S1).
+ Open protocol
+ Expand
4

Gene Expression Profiling of TLR9 and MyD88 Knockdown

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were transduced with shRNAs, puro-selected and harvested at indicated times after shRNA induction. RNA was isolated using RNEasy mini kits (Qiagen). Gene expression was assessed using two-color human Agilent 4 × 44K gene expression arrays following the manufacturers protocol. Briefly, control shSC4 (control, Cy3-labelled) RNA was compared to RNA from cells with shRNAs targeting TLR9 (C4), TLR9 (D7), MyD88 (A7), MyD88 (B3) (Cy5-labelled) at each of the indicated time points. Array elements were filtered for spot quality using Agilent Feature Extraction software version 10.7, specific genes were determined to be downregulated if the log2 fold change (comparing control shSC4 to shRNA for TLR9) was less than −0.3 for at least 3 of the 4 time points (shTLR9) per cell line. Gene expression data have been deposited in Gene Expression Omnibus (GEO) under accession GSE99276. Signature enrichment was performed as previously described 32 (link). Briefly, downregulated genes were tested for overlap with published gene signatures in a 2×2 contingency table using a Fisher’s exact test.
+ Open protocol
+ Expand
5

Gene Expression Analysis of DLBCL Cell Lines Treated with ND-2158

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four ABC DLBCL cell lines (OCI-Ly10, TMD8, HBL1, and OCI-Ly3), were treated with either 10 µM ND-2158 or 10 µM of the structurally related negative control compound ND-1659 for 6, 12, 24, or 36 h in culture. Cells were harvested at each time point, and RNA for gene expression was prepared from 5 million cells using TRIzol (Invitrogen) extraction, followed by clean up using the RNeasy kit (QIAGEN). Gene expression profiling was performed using two-color human Agilent 4 × 44K gene expression arrays (Agilent Technologies), as described by the manufacturer, comparing signal from control compound-treated (ND-1659) control cells (Cy3) with cells treated with ND-2158 (Cy5) for the indicated times. Array elements were filtered for those meeting confidence thresholds for spot size, architecture, and level above local background. These criteria are a feature of the Agilent Technologies gene expression software package for Agilent 4 × 44K arrays. Gene expression signature enrichment was performed by comparing changes in gene expression from at least two ABC DLBCL cell lines, occurring in at least two time points after ND-2158 treatment. Gene expression signature enrichment analysis was performed as described previously (Yang et al., 2012 (link)). Gene expression data has been deposited under GEO accession no. GSE63029.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!